Phosphorylation of BRN2 Modulates Its Interaction with the Pax3 Promoter to Control Melanocyte Migration and Proliferation

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2012 Feb 1

PMID 22290434

Citations 12

Authors

Irina Berlin

Laurence Denat

Anne-Lise Steunou

Isabel Puig

Delphine Champeval

Sophie Colombo

Karen Roberts

Elise Bonvin

Yveline Bourgeois

Irwin Davidson

Veronique Delmas

Laurence Nieto

Colin R Goding

Lionel Larue

Affiliations

Soon will be listed here.

Abstract

MITF-M and PAX3 are proteins central to the establishment and transformation of the melanocyte lineage. They control various cellular mechanisms, including migration and proliferation. BRN2 is a POU domain transcription factor expressed in melanoma cell lines and is involved in proliferation and invasion, at least in part by regulating the expression of MITF-M and PAX3. The T361 and S362 residues of BRN2, both in the POU domain, are conserved throughout the POU protein family and are targets for phosphorylation, but their roles in vivo remain unknown. To examine the role of this phosphorylation, we generated mutant BRN2 in which these two residues were replaced with alanines (BRN2TS→BRN2AA). When expressed in melanocytes in vitro or in the melanocyte lineage in transgenic mice, BRN2TS induced proliferation and repressed migration, whereas BRN2AA repressed both proliferation and migration. BRN2TS and BRN2AA bound and repressed the MITF-M promoter, whereas PAX3 transcription was induced by BRN2TS but repressed by BRN2AA. Expression of the BRN2AA transgene in a Mitf heterozygous background and in a Pax3 mutant background enhanced the coat color phenotype. Our findings show that melanocyte migration and proliferation are controlled both through the regulation of PAX3 by nonphosphorylated BRN2 and through the regulation of MITF-M by the overall BRN2 level.

Citing Articles

Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.

Huang F, Santinon F, Flores Gonzalez R, del Rincon S Front Oncol. 2021; 11:756001.

PMID: 34604096 PMC: 8481945. DOI: 10.3389/fonc.2021.756001.

BRN2 is a non-canonical melanoma tumor-suppressor.

Hamm M, Sohier P, Petit V, Raymond J, Delmas V, Le Coz M Nat Commun. 2021; 12(1):3707.

PMID: 34140478 PMC: 8211827. DOI: 10.1038/s41467-021-23973-5.

MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma.

Zhao G, Wei Z, Guo Y Biol Res. 2020; 53(1):11.

PMID: 32169117 PMC: 7071777. DOI: 10.1186/s40659-020-00278-3.

CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations.

Okuno H, Renault Mihara F, Ohta S, Fukuda K, Kurosawa K, Akamatsu W Elife. 2017; 6.

PMID: 29179815 PMC: 5705211. DOI: 10.7554/eLife.21114.

Prenatal diagnosis and genetic counseling for Waardenburg syndrome type I and II in Chinese families.

Wang L, Qin L, Li T, Liu H, Ma L, Li W Mol Med Rep. 2017; 17(1):172-178.

PMID: 29115496 PMC: 5780116. DOI: 10.3892/mmr.2017.7874.

References

Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D . Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene. 2011; 30(20):2319-32. DOI: 10.1038/onc.2010.612. View

Lee M, Goodall J, Verastegui C, Ballotti R, Goding C . Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. J Biol Chem. 2000; 275(48):37978-83. DOI: 10.1074/jbc.M003816200. View

Carreira S, Goodall J, Aksan I, La Rocca S, Galibert M, Denat L . Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005; 433(7027):764-9. DOI: 10.1038/nature03269. View

Schwahn D, Xu W, Herrin A, Bales E, Medrano E . Tyrosine levels regulate the melanogenic response to alpha-melanocyte-stimulating hormone in human melanocytes: implications for pigmentation and proliferation. Pigment Cell Res. 2001; 14(1):32-9. DOI: 10.1034/j.1600-0749.2001.140106.x. View

Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M . Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007; 21(22):2923-35. PMC: 2049194. DOI: 10.1101/gad.450107. View

Hanke T, Szawlowski P, Randall R . Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol. 1992; 73 ( Pt 3):653-60. DOI: 10.1099/0022-1317-73-3-653. View

Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek K . Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006; 20(24):3426-39. PMC: 1698449. DOI: 10.1101/gad.406406. View

Nieto L, Joseph G, Stella A, Henri P, Burlet-Schiltz O, Monsarrat B . Differential effects of phosphorylation on DNA binding properties of N Oct-3 are dictated by protein/DNA complex structures. J Mol Biol. 2007; 370(4):687-700. DOI: 10.1016/j.jmb.2007.04.072. View

Saijoh Y, Ikeda M, Ichikawa M, Hamada H . Predominant expression of Brn-2 in the postmitotic neurons of the developing mouse neocortex. Brain Res. 1997; 752(1-2):261-8. DOI: 10.1016/s0006-8993(96)01472-2. View

10.

Castro D, Skowronska-Krawczyk D, Armant O, Donaldson I, Parras C, Hunt C . Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev Cell. 2006; 11(6):831-44. DOI: 10.1016/j.devcel.2006.10.006. View

11.

Tamura A, Halaban R, Moellmann G, Cowan J, Lerner M, LERNER A . Normal murine melanocytes in culture. In Vitro Cell Dev Biol. 1987; 23(7):519-22. DOI: 10.1007/BF02628423. View

12.

Cook A, Sturm R . POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res. 2008; 21(6):611-26. DOI: 10.1111/j.1755-148X.2008.00510.x. View

13.

Kubic J, Young K, Plummer R, Ludvik A, Lang D . Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res. 2008; 21(6):627-45. PMC: 2979299. DOI: 10.1111/j.1755-148X.2008.00514.x. View

14.

Hara Y, Rovescalli A, Kim Y, Nirenberg M . Structure and evolution of four POU domain genes expressed in mouse brain. Proc Natl Acad Sci U S A. 1992; 89(8):3280-4. PMC: 48850. DOI: 10.1073/pnas.89.8.3280. View

15.

Diamond S, Chiono M, Gutierrez-Hartmann A . Reconstitution of the protein kinase A response of the rat prolactin promoter: differential effects of distinct Pit-1 isoforms and functional interaction with Oct-1. Mol Endocrinol. 1999; 13(2):228-38. DOI: 10.1210/mend.13.2.0227. View

16.

Kapiloff M, Farkash Y, Wegner M, Rosenfeld M . Variable effects of phosphorylation of Pit-1 dictated by the DNA response elements. Science. 1991; 253(5021):786-9. DOI: 10.1126/science.1652153. View

17.

Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R . Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008; 3(7):e2734. PMC: 2444043. DOI: 10.1371/journal.pone.0002734. View

18.

Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer B, Buckingham M . The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 2003; 17(23):2950-65. PMC: 289153. DOI: 10.1101/gad.281203. View

19.

Swope V, Medrano E, Smalara D, Abdel-Malek Z . Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res. 1995; 217(2):453-9. DOI: 10.1006/excr.1995.1109. View

20.

Thomson J, Murphy K, Baker E, Sutherland G, Parsons P, Sturm R . The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene. 1995; 11(4):691-700. View